Impairment of gastrointestinal function or GI disease that may significantly alter the absorption of oral combination partners.
Impairment of gastrointestinal function or GI disease that may significantly alter the absorption of oral combination partners
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Gastrointestinal (GI) function or disease that may significantly alter the absorption of the study drugs
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Patient must be able to take oral medications; patients may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study drug
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral vemurafenib
Patient must be able to take oral medications; patients may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study drug
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Patients with a known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Known impairment of gastrointestinal function that would alter drug absorption.
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Impairment of gastrointestinal function/disease that may significantly alter the absorption of everolimus.
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral Everolimus;
